Cellular effects of everolimus and sirolimus on podocytes. - Wikidata - awgldk - TriplyDB

Cellular effects of everolimus and sirolimus on podocytes.

Cellular effects of everolimus and sirolimus on podocytes.

http://www.wikidata.org/entity/Q35048950

about

Drug-induced glomerular disease: direct cellular injury.Renal Lipotoxicity-Associated Inflammation and Insulin Resistance Affects Actin Cytoskeleton Organization in Podocytes Recessive nephrocerebellar syndrome on the Galloway-Mowat syndrome spectrum is caused by homozygous protein-truncating mutations of WDR73.mTOR inhibitors and renal allograft: Yin and Yang.Everolimus and sirolimus in transplantation-related but different.Podocyte directed therapy of nephrotic syndrome-can we bring the inside out?Effect of benfotiamine in podocyte damage induced by peritoneal dialysis fluid.Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.The role of sirolimus in proteinuria in diabetic nephropathy rats.The activation of mTOR is required for monocyte pro-inflammatory response in patients with coronary artery disease.

P2860

Q27692666-243A97B3-AAE0-4F67-AA99-024A81C1204C Q35834459-EA8F8053-E2E8-40B9-8092-0291CED2F3A9 Q35880740-87F82A3A-F47B-4568-B794-C247E26167C8 Q38209973-F6A4D318-7102-4E6F-ABB6-2E446D0FFC83 Q38442560-7D4AD701-967A-4DD5-AC2E-5AABFE04BCC0 Q38458152-26A33755-6507-4046-BF3A-005E6E56F60B Q38895522-36FD31FF-084E-4273-94F8-D5BBF4533E6B Q38914374-7BF1C8C7-AB28-42DE-913E-0D568A8C89AD Q38962103-77CD4E56-3BE6-4BE8-AD6D-5B4E2D51A8D6 Q47168870-25C17408-E652-4CB6-8E41-206236289940 Q51312253-2093348B-F80B-4370-B23F-1315741D7DB5

P2860

Cellular effects of everolimus and sirolimus on podocytes.

http://www.wikidata.org/entity/Q35048950

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Cellular effects of everolimus and sirolimus on podocytes.

@ast

Cellular effects of everolimus and sirolimus on podocytes.

@en

type

label

Cellular effects of everolimus and sirolimus on podocytes.

@ast

Cellular effects of everolimus and sirolimus on podocytes.

@en

prefLabel

Cellular effects of everolimus and sirolimus on podocytes.

@ast

Cellular effects of everolimus and sirolimus on podocytes.

@en

P1433

Q35048950-B7C55C99-BC96-4201-A6AD-79429B37CDE7

P1476

Q35048950-37EFD0D0-F118-488E-AA60-0F8EAE80CB8A

P2093

Q35048950-098948F1-DDB0-49C6-B907-179022B69485

Q35048950-14F78F9D-CE1F-473C-B5EA-B2D0DEA5EFB4

Q35048950-15146D09-0358-4753-8859-24370025BAEB

Q35048950-84D0B68F-582E-4AFD-BFA7-5AB3C345E908

Q35048950-906A57DB-A1F0-46DC-B564-F4B6B4467BB6

Q35048950-A4BB3AB6-E7BF-46E5-A5F5-DF6EF9ACF901

Q35048950-EF1BC4BC-2B1D-4284-A107-86A79EB11577

P2860

Q35048950-02902843-0336-4E1C-93C1-2208F7D4FD24

Q35048950-058E1CC8-0952-40D3-8A83-314887F3B7C7

Q35048950-086325C4-57BA-41EF-A864-84673FD3E5EC

Q35048950-08A6869B-BE88-4D6D-9E5F-7E8CA0CA77A3

Q35048950-0A50F088-F672-4505-8EE3-5F6E607B639E

Q35048950-0B577091-9287-4BBF-ACB6-863C9D23A06C

Q35048950-0BE8716E-171B-42B6-B7F9-BC673586AB7A

Q35048950-0DA759EB-A5DB-405B-947F-7FFCD1FEAB9B

Q35048950-1505A0CE-098E-4E28-AA88-F41B640CD69A

Q35048950-22832DB0-6BAA-4A4E-AE83-B98458C48E6A

P304

Q35048950-9CAF2756-B19D-4421-A147-D8281B63E1E6

P31

Q35048950-FEFD6B10-316F-426D-8726-71E8E4187607

P356

Q35048950-502EB6F3-C0C0-422F-AFD5-B0FE09473C31

P407

Q35048950-B9336683-FA85-446D-B096-197505BBFCC6

P433

Q35048950-0EC62171-C13C-4686-825E-B08D12F8C048

P478

Q35048950-24D67A9A-6290-41C8-9604-4F5C17569DBD

P577

Q35048950-3E167FB3-F3C2-46EA-8013-675DAE0E5E69

P5875

Q35048950-7EEBEEE0-FC66-439F-865E-6C6F317B2537

P698

Q35048950-13C53EF1-4C7A-42E4-9667-31E0E7D2C470

P932

Q35048950-50CEF398-7E52-4801-8DEB-1A99920DBC95

P356

JOURNAL.PONE.0080340

P1433

P1476

Cellular effects of everolimus and sirolimus on podocytes.

@en

P2093

Jochen Reiser

http://www.w3.org/2001/XMLSchema#string

Julia Tsobaneli

http://www.w3.org/2001/XMLSchema#string

Lars P Kihm

http://www.w3.org/2001/XMLSchema#string

Lena Weber

http://www.w3.org/2001/XMLSchema#string

Martin Zeier

http://www.w3.org/2001/XMLSchema#string

Sandra Müller-Krebs

http://www.w3.org/2001/XMLSchema#string

Vedat Schwenger

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Synaptopodin regulates the actin-bundling activity of alpha-actinin in an isoform-specific manner

Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control

Chronic renal failure after transplantation of a nonrenal organ

Interaction with podocin facilitates nephrin signaling

Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling

A mammalian protein targeted by G1-arresting rapamycin-receptor complex

Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome

Everolimus and sirolimus in combination with cyclosporine have different effects on renal metabolism in the rat

Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy.

P304

e80340

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0080340

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258825960

http://www.w3.org/2001/XMLSchema#string

P698

24260371

http://www.w3.org/2001/XMLSchema#string

P932

3829970

http://www.w3.org/2001/XMLSchema#string